Back to School: How biopharma can reboot drug development. Access exclusive analysis here

Words of wisdom

Alejandro Zaffaroni, founder of Syntex Corp., Alza Corp., DNAX Ltd. and Affymax N.V., which was just sold to Glaxo plc for $533 million, is in no hurry to do it all again. But he does have a vision of the hot areas in biotech and how others in the industry should go forward with new startup companies, which he shared with BioCentury last week. The following recounts his Commentary on the future.

To determine the direction of the industry,

Read the full 789 word article

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE